Literature DB >> 36169895

Feedback loop between fatty acid transport protein 2 and receptor interacting protein 3 pathways promotes polymorphonuclear neutrophil myeloid-derived suppressor cells-potentiated suppressive immunity in bladder cancer.

Xiaojun Shi1, Shiyu Pang2, Jiawei Zhou2, Guang Yan2, Jie Sun3, Wanlong Tan2.   

Abstract

BACKGROUND: Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) promote tumor immune tolerance and cause tumor immunotherapy failure. In this study, we found that high PMN-MDSCs infiltration, overexpressed fatty acid transporter protein 2 (FATP2) and underexpressed receptor-interacting protein kinase 3 (RIPK3) existed in the mouse and human bladder cancer tissues. However, the related mechanisms remain largely unknown. METHODS AND
RESULTS: Both FATP2 and RIPK3 expressions were associated with clinical stage. FATP2 knockout or up-regulating RIPK3 reduced the synthesis of prostaglandin E2 (PGE2) in PMN-MDSCs, attenuated the suppressive activity of PMN-MDSCs on CD8+ T cells functions and inhibited the tumor growth. There was a PGE2-mediated feedback loop between FATP2 and RIPK3 pathways, which markedly promoted the immunosuppressive activity of PMN-MDSCs. Combination therapy with inhibition of FATP2 and activation of RIPK3 can effectively inhibit tumor growth.
CONCLUSIONS: This study demonstrated that a feedback loop between FATP2 and RIPK3 pathways in PMN-MDSCs significantly promoted the synthesis of PGE2, which severely impaired the CD8+ T cell functions. This study may provide new ideas for immunotherapy of human bladder cancer.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Bladder cancer; Fatty acid transporter protein 2; Immunotherapy; PMN-MDSCs; Receptor-interacting protein kinase 3

Year:  2022        PMID: 36169895     DOI: 10.1007/s11033-022-07924-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  1 in total

Review 1.  Immune escape mechanisms and immunotherapy of urothelial bladder cancer.

Authors:  Zhao Yang; Yinyan Xu; Ying Bi; Nan Zhang; Haifeng Wang; Tianying Xing; Suhang Bai; Zongyi Shen; Faiza Naz; Zichen Zhang; Liqi Yin; Mengran Shi; Luyao Wang; Lei Wang; Shihui Wang; Lida Xu; Xin Su; Song Wu; Changyuan Yu
Journal:  J Clin Transl Res       Date:  2021-07-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.